Ewopharma AG

4 articles about Ewopharma AG

• Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication

  1/30/2024

  Can-Fite BioPharma Ltd today announced that it has expanded its out licensing transaction with Ewopharma AG. to include the pancreatic cancer indication of Can-Fite.

• Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma

  3/16/2021

  $2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included

• Eisai Company And Ewopharma Announce Commercial Partnership In Central Eastern Europe For Halaven, Targretin And Zonegran

  6/23/2017

• Ewopharma Release: Company Partners With Biogen To Commercialise BENEPALI And FLIXABI In Central Eastern Europe

  1/23/2017